Biomacromolecules, Journal Year: 2025, Volume and Issue: unknown
Published: May 5, 2025
Sinomenine hydrochloride (SH) has been clinically utilized for many years to treat rheumatoid arthritis (RA) in both oral and injectable forms. However, its low bioavailability, poor targeting, high dosage requirements, side effects, present significant challenges. This study developed folic acid-carboxymethyl chitosan-modified sinomenine-curcumin nanopolymers (named SCNP) the targeted treatment of RA, reduce effects. The design SCNP employs acid (FA) as a targeting moiety, facilitating specific binding folate receptor (FR) on surface macrophages enabling internalization into activated via endocytosis, thereby achieving delivery sites inflammation. In rat cell model was found decrease reactive oxygen species (ROS) pro-inflammatory factors while increasing anti-inflammatory factor IL-10 through NF-κB/NLRP3 pathway. These findings indicate that potential lower drug dosage, enhance therapeutic efficacy, minimize effects such diarrhea rash, highlighting promise an inflammation-targeting nanopolymer.
Language: Английский